Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations
Clinical trial NCT02607813 · TERMINATED
Trial details
- NCT number
- NCT02607813
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-01-18
- Primary completion
- 2022-02-18
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.